Pressure BioSciences Inc. (PBIO)
|Net Income (ttm)||-17.58M|
|Trading Day||May 7|
|Day's Range||1.89 - 2.01|
|52-Week Range||1.30 - 3.95|
Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2020 Financial Results and Provide Business Update
Conference Call Scheduled for Wednesday, April 21st at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / April 19, 2021 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that ...
Company Expects Acquisition to be Accretive with Sustained Profitable Revenue Growth, Leveraging Market-Changing Synergy from PBI's Ultra Shear Technology Nanoemulsions Platform SOUTH EASTON, MA / ACCES...
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the Americas, Europe, Asia, Africa, and Australia. Its pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. It als... [Read more...]
|IPO Date |
Oct 31, 1996
|Stock Exchange |
|Ticker Symbol |
In 2020, PBIO's revenue was $1.22 million, a decrease of -32.56% compared to the previous year's $1.81 million. Losses were -$16.01 million, 37.3% more than in 2019.
The average 12-month stock price forecast for PBIO is 1.57, which is a decrease of -21.50% from the latest price.